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gp120 resistance mutationsThe HIV-1 CCR5 co-receptor is a member of the chemokine receptor family of G-protein coupled receptors;
for which a number of small molecule antagonists, such as vicriviroc (VCV), have been developed to inhibit
HIV-1 R5-tropic replication. In this study, we analyzed an HIV-1 subtype D envelope gene from a clinical trial
subject who developed complete resistance to VCV. The HIV-1 resistant envelope has six predominant amino
acid changes in the V3 loop, together with one change in the C4 domain of gp120, which are fully responsible
for the resistance phenotype. V3 loop mutations Q315E and R321G are essential for resistance to VCV,
whereas E328K and G429R in C4 contribute signiﬁcantly to the infectivity of the resistant variant.
Collectively, these amino acid changes inﬂuenced the interaction of gp120 with both the N-terminus and
ECL2 region of CCR5.es, 2015 Galloping Hill Road,
1 908 740 3918.
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
HIV-1 infects CD4 positive target cells through one or both of two
chemokine receptors—CC motif chemokine receptor 5 (CCR5) and
CXC chemokine receptor 4 (CXCR4). The initial interaction between
the envelope glycoprotein gp120 homotrimers and CD4 induces a
conformational change in gp120 that enables binding to either CCR5
or CXCR4 co-receptors (Wyatt and Sodroski, 1998). In the case of
CCR5, the co-receptor binding domain in gp120 is formed largely by
the V3 loop and C4 domain in the bridging sheet region (Huang et al.,
2007, 2005; Rizzuto and Sodroski, 2000; Rizzuto et al., 1998; Wyatt et
al., 1998; Wyatt and Sodroski, 1998). The coordinated interactions
between gp120 and the co-receptor produce additional conforma-
tional changes within the gp120/gp41 trimer that leads to triggering
of the gp41 fusion peptide and subsequent fusion of virus and cell
membranes.
Small molecule CCR5 co-receptor antagonists that block HIV-1
infection bind in a pocket formed by the transmembrane domains of
CCR5. The drug-bound co-receptor locks into a conformation whichsubsequently inhibits R5-tropic HIV-1 entry of host cells (Dragic et al.,
2000; Kondru et al., 2008; Maeda et al., 2006; Nishikawa et al., 2005;
Seibert et al., 2006; Tsamis et al., 2003). One CCR5 antagonist,
maraviroc (MVC), marketed in the US as Selzentry® is approved for
use in both naïve and treatment-experienced adult patients (Gulick et
al., 2008). Another CCR5 antagonist, vicriviroc (VCV), is currently in
late-stage clinical trials (Gulick et al., 2007; Schurmann et al., 2007).
Additional understanding of the biology of viral resistance mechan-
isms associated with this class of inhibitors and identiﬁcation of
signature genotypic changes in the envelope glycoprotein that impart
resistance would help further optimize the clinical use of these agents.
Clinical failure with CCR5 co-receptor antagonists has most often
correlated with the expansion of pre-existing, low-level X4 using
virus (Gulick et al., 2008, 2007; Landovitz et al., 2008; Moore and
Kuritzkes, 2009; Pﬁzer, Inc., 2007; Tsibris et al., 2008), but classical
resistance to CCR5 antagonists has also been reported (Gulick et al.,
2008, 2007; Pﬁzer, Inc., 2007; Tsibris et al., 2008). In phase II studies
for VCV, 1/29 subjects who failed therapy in the ACTG A5211 study
(Gulick et al., 2007; Tsibris et al., 2008) and 4/26 subjects in the
P03802 trial (Landovitz et al., 2008) developed R5 variants with
phenotypic resistance to VCV. How R5-resistant variants evolve in
clinical subjects has not been well characterized. In the single study
subject that was characterized, changes in the V3 loop of gp120 were
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(Tsibris et al., 2008).
R5-tropic resistant variants selected in-vitro were shown to have
adapted to use the drug-bound form of CCR5 (Marozsan et al., 2005;
Moore and Kuritzkes, 2009; Ogert et al., 2008; Pugach et al., 2007;
Tsibris et al., 2008; Westby et al., 2007) and recent ﬁndings show that
two lab-adapted resistant viruses acquired increased dependence on
the N-terminus of CCR5 for viral entry (Berro et al., 2009; Ogert et al.,
2009). In this report, we describe the analysis of 7 mutations present
in the CCR5 binding site region of gp120 (6 V3 loop mutations and 1
C4 mutation) identiﬁed in a clinical subject who developed complete
phenotypic resistance to VCV while participating in a phase II trial.
These mutations were systematically characterized for their effect on
VCV resistance and interactions with CCR5.Results
Subject 91 (S91) characteristics
S91 from clinical study P03802 (Landovitz et al., 2008) receiving a
regimen of zidovudine+lamivudine in combination with 75 mg VCV
QD had a baseline viral load of approximately 105 RNA c/ml. This
subject experienced nearly complete viral suppression having a nadir
viral load (97 c/ml) on day 57. This subject continued on treatment
and maintained a stable viral load (103 c/ml) from week 14 until
study discontinuation at week 48. The CD4 cell count for S91
increased from 188/mm3 at baseline to 351/mm3 at week 48. As
previously reported (Landovitz et al., 2008), VCV plasma Cmin
concentrations exceeding 100 ng/ml were associated with virologic
success and S91 had a VCV Cmin plasma concentration of 95 ng/ml.
HIV-1 from S91 was categorized as subtype D and at study
discontinuation was reported to be R5-tropic by the Troﬁle™ assay
(Whitcomb et al., 2007). Susceptibility to VCV was determined using
the PhenoSense Entry™ assay; end of treatment viral pools exhibited
phenotypic resistance to VCV with a maximum percent inhibition
(MPI) of 34.5%. MPI values measured in pseudovirus drug suscepti-
bility assays are used as a representative measure of resistance to co-
receptor antagonists based on the nature of the allosteric effect these
inhibitors have on CCR5 and the ability of HIV-1 to adapt by using the
drug-bound form of CCR5 (Buontempo et al., 2009; Moore and
Kuritzkes, 2009; Pugach et al., 2007, 2009; Westby et al., 2007).Sequence analysis of S91 envelope clones
The HIV-1 envelope gene was ampliﬁed from samples obtained at
baseline, week 24, and study discontinuation at week 48. Envelope
sequences were analyzed for speciﬁc amino acid changes in the V3
loop and C4 domain which represent the principal CCR5 co-receptor
binding regions in gp120 (Huang et al., 2007, 2005; Rizzuto et al.,
1998; Wu et al., 1996; Wyatt et al., 1998). 12 clones from each time
point were sequenced and the V3 loop amino acids for each clone are
shown in Fig. 1A. The sequence of the V3 loop/bridging sheet region of
S91 gp120 present in themajority of clones at week 48 are highlighted
in the molecular model of the gp120-CD4 complex in Fig. 1B.
Sequence analysis of subtype D viruses in the Los Alamos HIV-1
database and the frequency of amino acids at each of these S91
positions were determined. The subtype D analysis showed the
following results: positions 309-F (0%), L (4.4%), I (82.2%); 314-G
(92.9%), W(0%); 315-Q (54.1%), E (0.6%); 317-L (48.3%), F (21.1%);
320-D (3.1%); 321-R (14.6%), G (22.8%), K (22.8%); 328-E (0.7%), K
(7.6%), Q (65.1%); and 429-G (61.2%), R (3.7%). Of special note, the D
(N) amino acid at position 320 in V3 was present in only 43/1367
subtype D envelope sequences in the public HIV-1 database and
therefore can be considered a rare insertion mutation.Analysis of S91Baseline and S91Wk 48 replication competent HIV-1
produced with pNL4-3/S91 gp160 provirus constructs
Replicating cultures of S91Baseline and S91Wk 48 HIV-1 were ana-
lyzed for susceptibility to VCV in U87-CD4-CCR5 cells. VCV dose–
response curves for S91Baseline HIV-1 showed susceptibility to VCV
with an IC50 of 1.3 nM; whereas, S91Wk 48 HIV-1 was completely
resistant to VCV with a MPI of−130% (Fig. 2A). Resistance was char-
acterized by replication enhancement in the presence of VCV at
concentrations ≥100 nM.
Pseudoviruses generated with chimeric ADA envelopes demonstrate
phenotypes similar to replication competent S91 HIV-1
We previously found that replacing the C2-V5 region of gp120 in a
VCV-susceptible R5-tropic ADA envelope with the corresponding
region derived from a lab-adapted VCV-resistant RU570 HIV-1 virus
was sufﬁcient to confer resistance to VCV (Ogert et al., 2009, 2008).
Using a similar strategy, we generated chimeric ADA envelopes with
the C2-V5 region derived from S91Baseline and S91Wk 48 clones.
S91Baseline pseudovirus was completely susceptible to VCV (IC50
0.5 nM; MPI 100%), whereas S91Wk 48 pseudovirus was completely
resistant to VCV with a MPI of −75% (Fig. 2B). The VCV-enhanced
pseudovirus entry phenotype correlates with the replication en-
hancement of S91Wk 48 HIV-1 in the presence of VCV.
To determine if the V3 loop alone would confer resistance to VCV;
we substituted the ADA V3 loop with the V3 loop from S91Baseline or
S91Wk 48 envelope. HIV-1 pseudoviruses generated with these
envelopes were tested for susceptibility to VCV. As shown in Fig. 2C,
both ADA and ADA V3 (S91Baseline) pseudoviruses were completely
susceptible to VCV (IC50 0.2 nM). However, when the V3 loop
sequence of ADA was replaced with the V3 loop from S91Wk 48
envelope (ADA V3 S91Wk 48), HIV-1 pseudoviruses were completely
resistant to VCV with a MPI of −50%.
We next asked if envelope clones ampliﬁed atweek 24might also be
resistant to VCV. The majority of envelope clones (7/12) at week 24
contain a nearly identical sequence as week 48 without a Q315E
mutation in the crown region of the V3 loop (Fig. 1A). To analyze this V3
loop sequence present at week 24, an E315Q back mutation was
generated in the S91Wk 48 envelope. Pseudoviruses produced were
characterizedbyVCVdose–response curves showingaMPI plateau level
at 91% (Table 1), thus demonstrating only a minimal reduction in
susceptibility to VCV. In order to analyze the other V3 loop sequence
found in 5/12 week 24 clones, step-wise forwardmutagenesiswasused
to construct this sequence within the context of the baseline clone.
Pseudoviruses producedwith this S91Wk 24V3 loop containing aG314W
mutation (Fig. 1A) demonstrated complete resistant to VCV with a MPI
of −25% (Table 1). However, by week 48, only 25% of the envelope
clones retained this speciﬁc V3 loop sequence (Fig. 1A). Because
envelope clones containing the Q315E crown mutation were predom-
inant at week 48, we focused the following studies using this envelope.
Phenotypic resistance to VCV is reproduced in the S91Baseline envelope
with a combination of 4 speciﬁc amino acid substitutions in the V3 loop
To establish the contribution for each V3 loop mutation on resis-
tance to VCV, forward amino acid substitutions were systematically
introduced into the S91Baseline envelope. The S91Baseline envelope with
a single amino acid substitution (Q315E, R321G or E328K) in V3 was
still completely susceptible to VCV with a MPI at 100% and an IC50
similar to S91Baseline pseudovirus. S91Baseline Q315E/L317F, S91Baseline
D320N/R321G, and S91Baseline F309L/L317F/D320N envelopes were
also completely susceptible to VCV when analyzed in pseudovirus
assays (Table 1). However, resistance to VCV was established with
speciﬁc combinations of ≥3 substitutions in the S91Baseline envelope.
The level of resistance to VCV varied based on the plateau level in the
Fig. 1. A) The V3 loop sequence of 12 individual envelope clones ampliﬁed from S91 at each time point: baseline, week 24 andweek 48. Amino acid numbering is based on the amino acid
coordinates for theHXB2 reference strain. The # clones identiﬁedwith the speciﬁc V3 loop sequence are shown. The aS91Baseline and bS91Wk 48 clones used inHIV-1 pseudovirus assays for
characterizing resistance toVCV. cThemaximumpercent inhibition (MPI) valuesdetermined fromVCVdose–response curvesusingHIV-1pseudoviruses (n≥3)generatedwith eachof the
designated envelopes are shown (n/t = not tested). The consensus sequence determined from analysis of subtype D viruses present in the public database (*—represents no amino acid
present). B). Molecular model of Subject 91 gp120/CD4 complex with designated amino acid changes that occurred between baseline and week 48 in the majority of envelope clones
sequenced.
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S91Baseline envelope containing Q315E/D320N/R321G, Q315E/L317F/
D320N/R321G, or Q315E/D320N/R321G/E328K forward mutations
were resistant to VCV with a MPI plateau level of 66%, 83%, and 33%,
respectively. The Q315E/D320N/R321G/E328K combination in the
S91Baseline envelope produced nearly complete resistance to VCV; how-
ever, this combination was unique showing increased virus infectivity
compared to either S91Baseline or S91Wk 48 pseudovirus (data not
shown).
By adding additional mutations, further variations in both
resistance and virus infectivity were observed. F309L in combination
with the Q315E/L317F/D320N/R321G mutations produced a sub-
stantial increase in resistance to VCV with a MPI at−385% (Table 1),
however virus infectivity was reduced N100-fold (data not shown).
The addition of L317F to the Q315E/D320N/R321G/E328K combina-
tion produced a similar MPI plateau level (Table 1), whereas all 6V3
loop substitutions together with G429R in C4 reproduced a VCVresistance phenotype that matched S91Wk 48 pseudovirus (Fig. 2B and
Table 1).
Subject 91 VCV-resistant virus remains R5-tropic
To determine if any of the V3 mutations acquired in S91 HIV-1
during treatment allowed for CXCR4 usage, we assayed the ability of
pseudoviruses generated with baseline, week 48, and baseline
envelopes containing different forward substitutions for infection of
U87-CD4-CXCR4 cells (Table 1). The HXB2 CXCR4 positive control
produced high relative light units (RLU) in U87-CD4-CXCR4 cells
(106 RLU) that was reduced to background RLU (103 RLU) with 1 µM
CXCR4 antagonist AMD3100. The RLU results for ADA R5-tropic
pseudovirus were also similar to the background RLU. Pseudoviruses
generated with S91Baseline, S91Wk 48, and S91Baseline envelopes
containing different forward substitutions did not infect U87-CD4-
CXCR4 cells, producing RLU results similar to background (103 RLU).
Fig. 2. A) VCV dose–response curves for S91baseline and S91Wk 48 replication competent
HIV-1. Data is average±SD of triplicates and is representative of 2 independent assays.
B) VCV dose–response curves for S91 ADA C2-V5Baseline and S91 ADA C2-V5Wk 48
envelopes. Data represents the average±SD of 4 replicates and is representative of 5
independent assays. C). VCV dose–response curves for○—ADA,■—ADAV3 (S91Baseline),
and□—ADA V3 (S91Wk 48) HIV-1 pseudoviruses. Data is the average±SD of 4 replicates
and represents results from 2 independent assays.
Table 1
Summary of results for single and combined VCV resistance mutations generated in the
S91Baseline envelope.
Forward mutations MPI EC50
(nM)
Tropisma
S91Baseline
(CIRPNNNTIKSVHFGPGQALYATDRIIGDIREAHC)
100 0.9 R5
Q315E 100 0.2
Q315E/L317F 100 0.4
R321G 100 0.4
D320N/R321G 100 0.8
E328K 100 1.0
F309L/L317F/D320N 100 0.8
Q315E/D320N/R321G 66 0.1 R5
Q315E/L317F/D320N/R321G 83 0.1 R5
Q315E/D320N/R321G/E328K 33 R5
Q315E/L317F/D320N/R321G/E328K 33 R5
F309L/Q315E/L317F/D320N/R321G −385 R5
F309L/Q315E/L317F/D320N/R321G/E328K −250 R5
F309L/G314W/L317F/D320N/R321G/E328Kb −25
F309L/L317F/D320N/R321G/E328K/G429Rb,c 91 5.1
F309L/Q315E/D320N/R321G/E328K/G429Rd 73 0.1
F309L/Q315E/L317F/D320N/E328K/G429Re 100 0.1
F309L/Q315E/L317F/D320N/R321G/E328K/G429R −60 R5
S91Wk 48
(CIRPNNNTIKSVHLGPGEAFYATNGIIGDIRKAHC)
−75 R5
ADA 100 0.2 R5
HXB2 X4
Bold data represent 6 V3-loop Mutations Found at Week 48.
a Tropism determined in U87-CD4-CCR5 and U87-CD4-CXCR4 cells.
b Week 24 V3 loop sequence.
c Reverse mutation E315Q in S91Wk 48 envelope.
d Reverse mutation F317L in S91Wk 48 envelope.
e Reverse mutation G321R in S91Wk 48 envelope.
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S91Wk 48 viral pools analyzed using the Troﬁle™ assay.
S91 VCV-resistant HIV-1 is more sensitive than S91Baseline virus to
inhibition with Mabs that speciﬁcally recognize either the N-terminus or
ECL2 region of CCR5
Monoclonal antibodies (Mabs) 2D7 and CTC5 were produced
following immunization with human CCR5 and have been previously
shown to speciﬁcally recognize either ECL2 or the N-terminus of CCR5,
respectively (Lee et al., 1999; Wu et al., 1997). In this study, these
Mabs were used to neutralize S91 pseudovirus infections in U87-CD4-
CCR5 cells in the presence and absence of VCV. S91Wk 48 virus was
inhibited to a similar degree by CTC5 anti-N-terminus Mab in the
presence or absence of VCV, as shown in Fig. 3A. Approximately 75% of
the virus infection was neutralized by the CTC5 Mab. In contrast,
S91Baseline virus was not susceptible to neutralization by CTC5 Mab.
Mab 2D7 which recognizes CCR5 ECL2 was previously shown to
inhibit entry of numerous R5-tropic strains of HIV-1 (Wu et al., 1997). In
Fig. 3B, complete inhibition of S91Baseline viruswasnot achievedwithMab
2D7 at concentrations ≤25 µg/ml. However, S91Wk 48 virus was
completely inhibited by Mab 2D7 at these concentrations (IC50 0.1 nM).
As the inset in Fig. 2B shows, when pseudovirus stocks are normalized to
p24andequivalent amounts of virus are assayed, S91Baseline virus is 4-fold
more infectious for unbound CCR5 than is S91Wk 48 virus. This provides a
rationale for the reduced sensitivity of the S91Baseline virus with thisMab.
In a similar vein, S91Wk 48 virus infectivity is increased N2-foldwith drug-
boundCCR5 (inset), thusmaking itmoredifﬁcult to inhibit S91Wk 48 virus
infection with MAb 2D7 in the presence of VCV (Fig. 3B).
Subject 91 VCV-resistant virus acquires an increase in dependence on the
N-terminus of CCR5
To probe speciﬁc interactions between S91Baseline and S91Wk 48
pseudovirus with CCR5, single point mutations Y3A, Y10A, D11A,
Fig. 3. Antibodyneutralization ofHIV-1pseudoviruseswithA)CTC5anti-N-terminusMAb
and B) 2D7 anti-ECL2 MAb. ○—S91Wk 48, ▲—S91Wk 48+10 µM VCV, and □—S91Baseline
HIV-1 pseudovirus. Inset: Infectivity of S91Baseline and S91Wk 48 HIV-1 pseudovirus
determined using equivalent levels of HIV-1 pseudovirus from p24 normalized stocks in
U87-CD4-CCR5 cells in the absence or presence (+VCV) of vicriviroc. Data represents the
average±SD of 4 replicates and represents results of 3 independent assays.
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(Δ 2–17) CCR5 deletion mutant were constructed and analyzed. The
infectivity of S91Baseline and S91Wk 48 pseudoviruses was assessed in
293T cells transiently expressing CD4 and each CCR5 mutant. The
expression levels on the surface of 293T cells for each CCR5 mutant as
well as co-expressed CD4 was determined by FACS using anti-CCR5
and anti-CD4 Mabs. The cell surface expression observed for CD4 and
each CCR5 mutant was similar to wt CCR5/CD4 expression (data not
shown). In addition, we previously reported the effects of each
mutation on ADA pseudovirus entry as a control (Ogert et al., 2009).
Fig. 4A shows the amino acids in the N-terminus of CCR5 based on
the structural model of the G-protein coupled β2-adrenergic receptor
(Cherezov et al., 2007). Each of the single point mutations that were
analyzed is designated. As shown in Fig. 4B, S91Baseline pseudovirus
infection was reduced by only 25% with either the Y3A or D11A
mutations compared to wt CCR5, whereas infection of cells expressing
the Y10A, N13A, Y14A, and Y15A mutations was reduced further to
approximately 40–50% of wt CCR5 infection, whereas S91Baseline
pseudovirus was unable to infect cells expressing the CCR5 Δ 2–17
deletion mutant. In terms of the S91Wk 48 VCV-resistant pseudovirus,
this virus was unable to infect cells expressing CCR5 with Y10A, D11A,
Y14A, or Y15A single point mutations either in the presence (data not
shown) or absence (Fig. 4C) of VCV. In contrast, infectivity N50% of wt
CCR5 infection was observed with cells expressing either the CCR5Y3A or N13A mutation. Similar to the S91Baseline virus, S91Wk 48 VCV-
resistant pseudovirus was unable to infect cells expressing the CCR5 Δ
2–17 mutant.
Molecular model predicts speciﬁc amino acids in the V3 loop of the
VCV-resistant envelope that make direct contacts with residues in the
N-terminus of CCR5
The potential structural implications of the S91Wk 48 adaptive
mutations in V3 were analyzed in structural models with either
S91Baseline or S91Wk 48 gp120/CD4complex and theCCR52–15N-terminus
peptide. We used Discovery Studio (Accelrys, San Diego, CA) to con-
struct homology models based on the previously reported structure
of the HIV-1 YU-2 gp120-CD4 complex docked with the CCR52–15
N-terminal peptide (Huang et al., 2007) and structural models of
CCR5 diagramed in Figs. 4A and 7B were based on the previously
published structural model of the G-protein coupled β2-adrenergic
receptor (Cherezov et al., 2007).
In the published structural model of the N-terminal peptide, the C4
aminoacidArg440gp120 in YU-2 forms an ionic interactionwithAsp11 in
theN-terminus of CCR5 (Huang et al., 2007). Inmodels constructedwith
the S91Baseline and S91Wk 48 envelopes, a similar interaction between
Lys440gp120 in C4 andAsp 11 in theN-terminus of CCR5 is also predicted
(Figs. 5A and B). However, in the S91Wk 48 envelope the additional
D320N/R321G mutations present in the stem region of the returning
strand of the V3-loop allow for the formation of an additional H-bond
between Asn 320gp120 and Asp 11 in the N-terminus (Fig. 5B). This
interaction is facilitated by the R321G mutation since Gly 321gp120
would relieve conformational constraints imposed by Arg 320gp120
present in the S91Baseline envelope. The Gly 321gp120 residue in the
resistant envelope enables the rotation of S91Wk 48 Asn 320gp120
allowing it to form an H-bond with Asp 11.
Themodel also predicts that the E328Kmutation in the base region
of V3 in the VCV-resistant envelope forms a new intra-molecular
contact within V3 (Fig. 5B). In the S91Baseline structural model, Glu
328gp120 and Asp 325gp120 both stabilize the highly conserved Arg
419gp120 residue in C4 (Fig. 5A). However, in the S91Wk 48 envelope,
Glu 328gp120 is replaced by Lys328gp120 which enables contact with
Asp325gp120 by rotating away from Arg 419gp120 in C4. Arg 419gp120 is
then able to form a new ionic interaction with the negatively charged
O-sulfated tyrosine at position 10 in the N-terminus (Fig. 5B). The
speciﬁc interactions predicted by these models are consistent with
results obtained when single alanine substitutions in the N-terminus of
CCR5 were made. Both Y10A and D11A abolished S91 VCV-resistant
pseudovirus entry, whereas S91Baseline pseudovirus entry was only
reduced approximately 50% compared to wt CCR5. Overall, the addi-
tional contacts predicted for theD320NandE328Kadaptivemutations in
conjunction with the interaction of R419 with Y10 support an improved
afﬁnity between VCV-resistant gp120 and the N-terminus of CCR5.
HIV-1 gp120 mutations at residues predicted to interact with the
N-terminus of CCR5 disrupt virus infectivity
To probe the contacts in gp120 predicted in the molecular models,
single alanine substitutions at positions 325, 327, 419 and 440 in VCV-
resistant gp120 were generated. Pseudoviruses produced with these
envelopes were analyzed together with S91Wk 48, S91Wk 48 N320D,
S91Wk 48 G321R, and S91Wk 48 K328E pseudoviruses in U87-CD4-CCR5
cells using p24 normalized pseudovirus stocks. Pseudovirus infections
in the absence (Fig. 6, left panel) or presence of 10 µMVCV (Fig. 6, right
panel) were compared to VCV-resistant S91Wk 48 pseudovirus.
Pseudoviruses generated with the S91Wk 48 envelope containing either
the D325A or R327A mutation were completely inactive in U87-CD4-
CCR5 cells; whereas the K440A mutation reduced pseudovirus
infectivity by 10-fold and both N320D and K328E mutations reduced
infectivity 5-fold. The G321R mutation reduced virus infectivity by b2-
Fig. 4. The effect of single alanine substitutions in the N-terminus of CCR5 on HIV-1 entry. A) Single alanine substitutions Y3A, Y10A, D11A, N13A, Y14A, and Y15A in the N-terminus
of CCR5 are depicted in a molecular diagram based on the previously published structural model of the G-protein coupled β2-adrenergic receptor (Cherezov et al., 2007). The results
of each single alanine substitution and a Δ 2–17 N-terminal amino acid mutant on B) S91Baseline and C) S91Wk 48 HIV-1 pseudovirus entry expressed as a percentage of wt CCR5
infection are the average±SD of ≥5 independent assays.
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In the presence of 10 µM VCV, both N320D and K440A mutations
reduced infectivity 10-fold, whereas the K328E mutation reduced
infectivity 3-fold with drug-bound CCR5. The R419A mutation had the
greatest impact on pseudovirus infections reducing infectivity N50-fold
with unbound CCR5 and 10-fold for the drug-bound co-receptor. The
amino acid at position 419 in the resistant envelope is predicted to form
anewcontactwith thenegatively charged sulfotyrosineatposition10 in
the N-terminus of CCR5. In agreement with this prediction, making a
conservative R419K mutation only reduced infection 2-fold with CCR5,
and virus entry via drug-bound CCR5 was unaffected.
In summary, single mutations at residues predicted to be
associated with binding of gp120 to the N-terminus of CCR5 predictedby our model primarily affected the overall ﬁtness of envelope on
virus entry. The N320D and K328E back mutations, as well as R327A,
R419A, and K440A alanine substitutions compromised virus infectiv-
ity with both the drug-free and drug-bound conformations of CCR5.
Together these results support the validity of the gp120 contacts
predicted in the structural homology model to interact with residues
in the N-terminus of CCR5.
K191A mutation in ECL2 disrupts VCV-resistant virus entry
To probe for speciﬁc contacts within the extra-cellular loop regions
of CCR5, single point mutations in both ECL2 and ECL3 were analyzed.
Single amino acid substitutions E172A, L174A, and C178A in ECL2
Fig. 5.Molecular model of A) S91 Baseline and B) S91 VCV-resistant gp120 in complex with CD4 and CCR52–15 N-terminus peptide based on coordinates previously reported for a
YU2/CD4 complex docked to the CCR52–15 N-terminus peptide (Huang et al., 2007).
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crown mutation could potentially interact with CCR5 through for-
mation of a salt bridge with a positively charged amino acid, single
alanine substitutions at each basic amino acid residue present in ECL2
(R168A, K171A, H175A, H181A, and K191A), ECL3 (R274A), and trans-
membrane domain 5 (K197A) of CCR5 were also analyzed.
Fig. 7A highlights the amino acid residues in the ECL2 region
of CCR5 that were changed to alanine. The ELC2 region shown in
this diagram is derived from a structural model of CCR5 based on the
G-protein coupled β2-adrenergic receptor (Cherezov et al., 2007). The
effect of each single alanine substitution on S91Baseline virus entry
expressed as a percentage of wt CCR5 activity is represented in Fig. 7B.
CCR5 C178A and H181A were the only ECL2 mutations that reduced
virus infectivity to ≤50% of wt CCR5 infectivity. The C178 residue was
previously shown to link ECL1 to ECL2 (Blanpain et al., 1999) and
likely disrupts the tertiary structure of ECL2. In ECL3, R274A had no
affect on entry of S91Baseline virus.The effects of each single alanine substitution on VCV-resistant
S91Wk 48 virus entry are depicted in Fig. 7C. The C178Amutation had a
similar effect on virus entry as was observed with S91Baseline virus
(≤25% wt CCR5 infection); whereas, the K191A mutation located at
the junction of ECL2 and the TM-5α-helix of CCR5, reduced infectivity
of VCV-resistant S91Wk 48 virus to b50% of wt CCR5 infection for the
unbound receptor (Fig. 7C, left panel).What is most remarkable is that
the K191A substitution in ECL2 completely disrupted VCV-resistant
virus entry with drug-bound CCR5 (Fig. 7C, right panel). Also, we
observed no effect on ADA virus entry for the K191Amutation in CCR5
(data not shown).
Discussion
The characterization of HIV-1 in S91 demonstrated that multiple
mutations in the V3 loop were needed to acquire resistance to VCV.
While a minimum of 3 amino acid changes in the S91Baseline envelope
Fig. 6. Infectivity of HIV-1 pseudoviruses expressed as the relative infection of S91Wk 48 pseudovirus. Single mutations were generated in the S91Wk 48 envelope and virus infectivity
is expressed relative to S91Wk 48 virus in the absence (left panel) or presence of VCV (right panel). Data is the average±SD of 4 replicates and results are representative of 3
independent assays.
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changes (Q315E/D320N/R321G/E328K) or more were required for
nearly complete phenotypic resistance. Although the Q315E/D320N/
R321G/E328K combination produced a phenotype with nearly
complete resistance, this combination was not present in any of the
envelope clones ampliﬁed from S91 HIV-1. Because the F309L/L317F/
D320N combination was common to all week 24 and week 48 clones,
it is likely the 2 clones at baseline with this combination (Fig. 1A)
represent the founder sequence from which the fully resistant clones
developed. It is interesting that the additional Q315E and R321G
mutations produced a highly resistant virus but infectivity was
particularly low with the drug-free receptor. The addition of E328K
and G429R resulted in a virus that was completely resistant to VCV
and also replicated efﬁciently using the drug-free receptor.
The S91 VCV-resistant HIV-1 is a subtype D virus and is a new
subtype for which resistance to VCV has not been previously char-
acterized. A subtype C virus was previously characterized and
mutations in the V3 loop alone were sufﬁcient to confer resistance
to VCV (Tsibris et al., 2008). While the pattern of amino acid muta-
tions in the two subtypes is quite different, both resistant subtypes
have 3 amino acid changes in the stem region of the returning strand
of the V3 loop. Resistance to VCV in this subtype D HIV-1 results in
part from an increased reliance on the N-terminus of CCR5 during
virus entry. This ﬁnding is similar to previous ﬁndings for two lab-
adapted HIV-1 resistant viruses (Berro et al., 2009; Ogert et al., 2009).
Previously, we demonstrated that a lab-adapted RU570 VCV-resistant
virus forms two new H-bonds with the N-terminus of CCR5 through a
K305Rmutation in V3 and P437Smutation in C4 (Ogert et al., 2009). It
is interesting that the S91 VCV-resistant virus is also predicted to
make two new contacts with the N-terminus of CCR5, but as the result
of 3 different V3 loop mutations: D320N, R321G, and E328K. If other
combinations of V3 loop changes can also impart structural changes
that enhance binding to the N-terminus of CCR5, this helps explain
why a signature pattern of resistance mutations has yet to be iden-
tiﬁed for VCV or other small molecule CCR5 antagonists. Structural
modeling and mutagenesis studies of additional HIV-1 isolates from
subjects resistant to CCR5 antagonists will help determine the
importance of enhanced recognition of the N-terminus of CCR5 for
clinical resistance.We also show that resistance to VCV in S91 is dependent on
an improved recognition of the ECL2 region of CCR5 as demon-
strated using MAb 2D7which speciﬁcally recognizes an epitope in the
N-terminal region of ECL2 in CCR5. Previous results have shown that
binding of VCV to CCR5 had essentially no effect on binding of Mab
2D7 to CCR5 (Ji et al., 2007) nor did several other small molecule CCR5
antagonists (Maeda et al., 2008). S91Wk 48 virus is more susceptible
to inhibition with Mab 2D7 in the absence of VCV than it is in the
presence of a saturating concentration of VCV. The increased
infectivity observed for the S91Wk 48 resistant virus with drug-
bound CCR5 is most likely mediated by an improved recognition of
an altered CCR5 conﬁguration induced by VCV. This, in turn, would
make it more difﬁcult to inhibit the S91Wk 48 resistant virus with
MAb 2D7 when the receptor is in a drug-bound state. Also, our ECL2
mutagenesis studies show that the K191A mutation in ECL2 ablates
S91Wk 48 virus entry only when the receptor is in the drug-bound
state. Preliminary homology models predict a potential for the for-
mation of a salt bridge between E315 in the V3 crown of S91Wk 48
gp120 and K191 located at the junction of ECL2 and the ﬁfth
transmembrane domain of CCR5. Additional mutagenesis/structural
modeling studies are ongoing in an attempt to conﬁrm this hypothesis
and the determination of additional interactions with other speciﬁc
residues in the extra-cellular regions of CCR5 that may be required for
S91Wk 48 entry.
Berro et al. (2009) propose that 4 V3-loop amino acid mutations in
a lab-adapted VCV-resistant HIV-1 CC101.19 impair interactions
between the V3-crown and CCR5 ECL2, while interactions with the
N-terminus of CCR5 are enhanced. The enhanced binding of HIV-1
CC101.19c17 envelope to the N-terminus is suggested to compensate
for a loss in the interaction between the V3 tip and ECL2 in CCR5
(Berro et al., 2009). This result is consistent with studies showing that
deletions in the V3-loop of dual-tropic, HIV-1 R3A (Laakso et al., 2007;
Nolan et al., 2009; Nolan et al., 2008) and HIV-2 VCP (Lin et al., 2007)
impart complete resistance to co-receptor antagonists suggested to be
a result of a loss of interaction between the V3 loop and CCR5 ECL2
(Agrawal-Gamse et al., 2009; Laakso et al., 2007; Nolan et al., 2009;
Nolan et al., 2008). However, more recent ﬁndings have shown that
adaptive mutations that allowed efﬁcient replication of HIV-1 R3A V3
(9, 9) produce an enhanced interaction with CD4 (Agrawal-Gamse et
Fig. 7. The effect of single alanine substitutions in ECL2 and ECL3 of CCR5 on HIV-1 pseudovirus entry. A) Single alanine substitutions R168A, K171A, E172A, L174A, H175A, C178A,
H181A, K191A in CCR5 ECL2 and K197A in transmembrane domain 5 are depicted in amolecular diagramof ECL2 based on the previously published structuralmodel for the G-protein
coupled β2-adrenergic receptor (Cherezov et al., 2007). The R274A mutation generated in ECL3 was also analyzed. The results of each single alanine substitution in CCR5 on
B) S91Baseline and C) S91Wk 48 HIV-1 pseudovirus entry in the absence (C, left panel) and presence of VCV (C, right panel) are expressed as a percentage ofwt CCR5 infection. Data is the
average±SD of 12 replicates per mutation and represents ≥2 independent assays.
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S91 HIV-1 developed complete resistance to vicriviroc as a result of
mutations that modiﬁed interactions between gp120 with residues in
both the N-terminus and ECL2 regions of CCR5.
The observation that multiple V3 mutations, were shown to
inﬂuence binding of gp120 to both the N-terminus and ECL2 regions
of CCR5, and were necessary to acquire resistance to VCV suggests a
high genetic barrier may exist for developing resistance to VCV. This
would also help explain the infrequent development of classical
resistance to this agent observed in clinical trials. In addition, it seemsplausible that the humoral immune systemmight have contributed to
selection of the S91Wk 48 virus containing the Q315E mutation. This
virus emerged between week 24 and week 48 as the resistant virus
containing mutation G314W at week 24 was reduced. However, to
support this observation neutralization studies using S91 serum are
needed. In addition to these ﬁndings, none of the combinedmutations
in the baseline envelope appeared to confer usage of CXCR4
supporting the clinical observation that the emergence of X4 virus
in clinical trials resulted from a pre-existing, minor population of X4
virus undetected at baseline.
154 R.A. Ogert et al. / Virology 400 (2010) 145–155Overall our studies suggest that the S91Wk 48 envelope adapted to
allow utilization of the drug-bound receptor by more efﬁciently using
both the N-terminus and ECL2 region of CCR5 during virus entry.
Further work with the S91Wk 48 envelope may increase our
understanding of the structural conformation of the drug-bound co-
receptor and provide insights into the timing of speciﬁc interactions
with the structural rearrangements that occur in the envelope trimer
during HIV-1 entry.
Materials and methods
Clinical study P03802
The clinical study design, study procedures, and statistical analysis
for study P03802 have been previously described (Landovitz et al.,
2008). Troﬁle™ and PhenoSense Entry™ assays were performed by
Monogram Biosciences.
Generation of Subject 91 ADA chimeric envelopes
pSV7d-ADA gp160 and pNL4-3E−Luc+ were obtained from Dr.
John Moore, Weill Medical College of Cornell University, New York,
NY. Envelope sequences for Subject 91 (S91) baseline (clone 28) and
week 48 (clone 15) were obtained from Monogram Biosciences.
Synthetic DNA clones encoding the entire gp160 in pUC57 were
generated by Bio Basic Inc. S91 chimeric ADA envelope clones were
constructed by ligation of pSV7d-ADA gp160 digested with Bgl II and
EcoN I and the corresponding fragments excised from S91 gp160.
Generation of pNL4-3/S91 baseline gp160 and pNL4-3/S91 week 48
gp160 provirus constructs
The pDOLHIVenv plasmid and pNL4-3 AD8 provirus construct
were obtained from the NIH AIDS Research and Reference Reagent
Program (Germantown, MD). A shuttle vector, pST-Blue-1/NL4-3
containing the EcoRI to XhoI fragment from pDOLHIVenv was
modiﬁed by placing a unique PacI site immediately downstream of
the gp160 coding sequence. The S91 gp160 coding sequences excised
using BbsI and PacI were sub-cloned into the pST-Blue-1/NL4-3 PacI.
EcoRI–XhoI fragments excised from the corresponding shuttle vector
were cloned directly into the pNL4-3-AD8 provirus construct to
produce infectious S91Baseline and S91Wk 48 HIV-1. NL4-3/S91Baseline
and NL4-3/S91Wk 48 virus stocks were generated in 293T cells using
ProFection® calcium phosphate transfection system (Promega).
VCV susceptibility assays with S91Baseline and S91Wk 48 replication
competent HIV-1
U87 astroglioma cells expressing CCR5 or CXCR4 and the U87-CD4
parental cell line were obtained from Dr. Dan Littman, New York
University. 10-fold serial dilutions of a VCV stock (ﬁnal concentration
10−5–10−15 M) were added to triplicate wells (5000 U87-CD4-CCR5
cells/well) and plates incubated at 37 °C for 1 h. Supernatants were
aspirated and replaced with HIV-1 and inhibitor and plates incubated
at 37 °C for 3 h. Virus was washed from wells 2 times with PBS and
cells cultured in media with VCV for 72 h at 37 °C. The extra-cellular
p24wasmeasured using Alliance HIV-1 p24 ELISA (PerkinElmer). VCV
dose–response data was expressed as the % inhibition of p24
production compared to control wells without VCV.
Site-directed mutagenesis (SDM) of Subject 91 chimeric envelope
SDMof amino acids in S91 chimeric ADA envelopes was performed
using QuikChange™ SDM kit (Stratagene) and sequence changes
veriﬁed by DNA sequence analysis. The following amino acid
mutations were generated in S91Baseline (F309L, G314W, Q315E,L317F, D320N, R321G, E328K, G429R, R419A, R419K, and K440A) and
S91Wk 48 (E315Q, F317L, N320D, G321R, K328E, R327A, R419A, R419K,
and K440A) envelopes. Amino acid changes are numbered according
to HXB2 reference strain coordinates using the Los Alamos National
Laboratory HIV sequence locator tool: (http://www.hiv.lanl.gov/
content/sequence/LOCATE/locate.html).
CCR5 mutations
The pcDNA3.1 CCR5 expression plasmid was obtained from Dr.
Dan Littman, New York University. The generation of mutations in the
N-terminus of CCR5 and in ECL2 (R168A, K171A, E172A, L174A, and
C178A) and co-expression of these CCR5 mutants with CD4 in 293T
cells were previously described (Ogert et al., 2009). Similar results
were observed when CCR5 mutants were expressed in the U87-CD4
parental cell line. Therefore, CCR5 mutations R274A in ECL3 and
H175A, H181A, K191A, K197A in ECL2 were analyzed in U87-CD4-
parental cells using FuGene® transfection reagent. U87-CD4 cells 24 h
post transfection were seeded into 96-well luminometer plates
(Perkin Elmer) at 5000 cells/well and plates were incubated
overnight at 37 °C. HIV-1 pseudovirus infections of transfected U87-
CD4 cells was performed as described below.
Generation and characterization of HIV-1 pseudoviruses
HIV-1 pseudoviruses were produced in 293T cells by calcium
phosphate transfection of pNL4-3E−Luc+ and HIV-1 envelope
expression vectors and pseudovirus assays were performed as
described previously (Ogert et al., 2009, 2008). For neutralization of
HIV-1 pseudovirus infection with CTC5 anti-N-terminus CCR5 MAb
(R&D Systems Inc., Minneapolis, MN; Catalog # MAB1802) and 2D7
anti-ECL2 CCR5 MAb (BD Pharmingen™, San Jose, CA; Catalog #
555991), serial 2-fold dilutions of Ab were added 1 h prior to the
addition of HIV-1 pseudovirus. % inhibition was calculated as follows:
100−(average normalized RLU for HIV-1 pseudovirus plus drug/
average normalized RLU for HIV-1 pseudovirus from control wells
without drug)×100.
References
Agrawal-Gamse, C., Lee, F.H., Haggarty, B., Jordan, A.P., Yi, Y., Lee, B., Collman, R.G.,
Hoxie, J.A., Doms, R.W., Laakso, M.M., 2009. Adaptive mutations in a human
immunodeﬁciency virus type 1 envelope protein with a truncated V3 loop restore
function by improving interactions with CD4. J. Virol. 83 (21), 11005–11015.
Berro, R., Sanders, R.W., Lu, M., Klasse, P.J., Moore, J.P., 2009. Two HIV-1 variants
resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry.
PLoS Pathog. 5 (8), e1000548.
Blanpain, C., Lee, B., Vakili, J., Doranz, B.J., Govaerts, C., Migeotte, I., Sharron, M., Dupriez,
V., Vassart, G., Doms, R.W., Parmentier, M., 1999. Extracellular cysteines of CCR5 are
required for chemokine binding, but dispensable for HIV-1 coreceptor activity.
J. Biol. Chem. 274 (27), 18902–18908.
Buontempo, P.J., Wojcik, L., Buontempo, C.A., Ogert, R.A., Strizki, J.M., Howe, J.A., Ralston,
R., 2009. Quantifying the relationship between HIV-1 susceptibility to CCR5
antagonists and virus afﬁnity for antagonist-occupied co-receptor. Virology 395
(2), 268–279.
Cherezov, V., Rosenbaum, D.M., Hanson, M.A., Rasmussen, S.G., Thian, F.S., Kobilka, T.S.,
Choi, H.J., Kuhn, P., Weis, W.I., Kobilka, B.K., Stevens, R.C., 2007. High-resolution
crystal structure of an engineered human beta2-adrenergic G protein-coupled
receptor. Science 318 (5854), 1258–1265.
Dragic, T., Trkola, A., Thompson, D.A., Cormier, E.G., Kajumo, F.A., Maxwell, E., Lin, S.W.,
Ying, W., Smith, S.O., Sakmar, T.P., Moore, J.P., 2000. A binding pocket for a small
molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc.
Natl. Acad. Sci. U. S. A. 97 (10), 5639–5644.
Gulick, R.M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., Nadler, J.,
Clotet, B., Karlsson, A., Wohlfeiler, M., Montana, J.B., McHale, M., Sullivan, J.,
Ridgway, C., Felstead, S., Dunne, M.W., van der Ryst, E., Mayer, H., 2008. Maraviroc
for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359 (14),
1429–1441.
Gulick, R.M., Su, Z., Flexner, C., Hughes, M.D., Skolnik, P.R., Wilkin, T.J., Gross, R.,
Krambrink, A., Coakley, E., Greaves, W.L., Zolopa, A., Reichman, R., Godfrey, C.,
Hirsch, M., Kuritzkes, D.R., 2007. Phase 2 study of the safety and efﬁcacy of
vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients:
AIDS Clinical Trials Group 5211. J. Infect. Dis. 196 (2), 304–312.
155R.A. Ogert et al. / Virology 400 (2010) 145–155Huang, C.C., Lam, S.N., Acharya, P., Tang, M., Xiang, S.H., Hussan, S.S., Stanﬁeld, R.L.,
Robinson, J., Sodroski, J., Wilson, I.A., Wyatt, R., Bewley, C.A., Kwong, P.D., 2007.
Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1
gp120 and CD4. Science 317 (5846), 1930–1934.
Huang, C.C., Tang, M., Zhang, M.Y., Majeed, S., Montabana, E., Stanﬁeld, R.L., Dimitrov, D.S.,
Korber, B., Sodroski, J., Wilson, I.A., Wyatt, R., Kwong, P.D., 2005. Structure of a V3-
containing HIV-1 gp120 core. Science 310 (5750), 1025–1028.
Ji, C., Zhang, J., Dioszegi, M., Chiu, S., Rao, E., Derosier, A., Cammack, N., Brandt, M.,
Sankuratri, S., 2007. CCR5 small-molecule antagonists and monoclonal antibodies
exert potent synergistic antiviral effects by cobinding to the receptor. Mol.
Pharmacol. 72 (1), 18–28.
Kondru, R., Zhang, J., Ji, C., Mirzadegan, T., Rotstein, D., Sankuratri, S., Dioszegi, M., 2008.
Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5
antagonists. Mol. Pharmacol. 73 (3), 789–800.
Laakso, M.M., Lee, F.H., Haggarty, B., Agrawal, C., Nolan, K.M., Biscone, M., Romano, J.,
Jordan, A.P., Leslie, G.J., Meissner, E.G., Su, L., Hoxie, J.A., Doms, R.W., 2007. V3 loop
truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and
enhanced sensitivity to neutralizing antibodies. PLoS Pathog. 3 (8), e117.
Landovitz, R.J., Angel, J.B., Hoffmann, C., Horst, H., Opravil, M., Long, J., Greaves, W.,
Fatkenheuer, G., 2008. Phase II study of vicriviroc versus efavirenz (both with
zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J. Infect.
Dis. 198 (8), 1113–1122.
Lee, B., Sharron, M., Blanpain, C., Doranz, B.J., Vakili, J., Setoh, P., Berg, E., Liu, G., Guy, H.R.,
Durell, S.R., Parmentier, M., Chang, C.N., Price, K., Tsang, M., Doms, R.W., 1999.
Epitope mapping of CCR5 reveals multiple conformational states and distinct but
overlapping structures involved in chemokine and coreceptor function. J. Biol.
Chem. 274 (14), 9617–9626.
Lin, G., Bertolotti-Ciarlet, A., Haggarty, B., Romano, J., Nolan, K.M., Leslie, G.J., Jordan, A.P.,
Huang, C.C., Kwong, P.D., Doms, R.W., Hoxie, J.A., 2007. Replication-competent
variants of human immunodeﬁciency virus type 2 lacking the V3 loop exhibit
resistance to chemokine receptor antagonists. J. Virol. 81 (18), 9956–9966.
Maeda, K., Das, D., Ogata-Aoki, H., Nakata, H.,Miyakawa, T., Tojo, Y., Norman, R., Takaoka,
Y., Ding, J., Arnold, G.F., Arnold, E., Mitsuya, H., 2006. Structural and molecular
interactions of CCR5 inhibitors with CCR5. J. Biol. Chem. 281 (18), 12688–12698.
Maeda, K., Das, D., Yin, P.D., Tsuchiya, K., Ogata-Aoki, H., Nakata, H., Norman, R.B., Hackney,
L.A., Takaoka, Y., Mitsuya, H., 2008. Involvement of the second extracellular loop and
transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into
the mechanism of allosteric inhibition. J. Mol. Biol. 381 (4), 956–974.
Marozsan, A.J., Kuhmann, S.E., Morgan, T., Herrera, C., Rivera-Troche, E., Xu, S., Baroudy,
B.M., Strizki, J., Moore, J.P., 2005. Generation and properties of a human
immunodeﬁciency virus type 1 isolate resistant to the small molecule CCR5
inhibitor, SCH-417690 (SCH-D). Virology 338 (1), 182–199.
Moore, J.P., Kuritzkes, D.R., 2009. A piece de resistance: how HIV-1 escapes small
molecule CCR5 inhibitors. Curr. Opin. HIV AIDS 4 (2), 118–124.
Nishikawa, M., Takashima, K., Nishi, T., Furuta, R.A., Kanzaki, N., Yamamoto, Y., Fujisawa,
J., 2005. Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-
220 on human CCR5. Antimicrob. Agents Chemother. 49 (11), 4708–4715.
Nolan, K.M., Del Prete, G.Q., Jordan, A.P., Haggarty, B., Romano, J., Leslie, G.J., Hoxie, J.A.,
2009. Characterization of a human immunodeﬁciency virus type 1 V3 deletion
mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-
bound receptor. J. Virol. 83 (8), 3798–3809.
Nolan, K.M., Jordan, A.P., Hoxie, J.A., 2008. Effects of partial deletions within the human
immunodeﬁciency virus type 1 V3 loop on coreceptor tropism and sensitivity to
entry inhibitors. J. Virol. 82 (2), 664–673.
Ogert, R.A., Ba, L., Hou, Y., Buontempo, C., Qiu, P., Duca, J., Murgolo, N., Buontempo, P.,
Ralston, R., Howe, J.A., 2009. Structure–function analysis of human immunodeﬁ-
ciency virus type 1 gp120 amino acid mutations associated with resistance to the
CCR5 coreceptor antagonist vicriviroc. J. Virol. 83 (23), 12151–12163.Ogert, R.A., Wojcik, L., Buontempo, C., Ba, L., Buontempo, P., Ralston, R., Strizki, J., Howe,
J.A., 2008. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using
heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-
V5 domain of gp120. Virology 373 (2), 387–399.
Pﬁzer, Inc., 2007. Maraviroc Tablets NDA 22–128: Antiviral Drugs Advisory Committee
(AVDAC) Brieﬁng Document. Pﬁzer Inc, New York, NY. http://www.fda.gov/
OHRMS/DOCKETS/AC/07/brieﬁng/.
Pugach, P., Marozsan, A.J., Ketas, T.J., Landes, E.L., Moore, J.P., Kuhmann, S.E., 2007. HIV-1
clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of
CCR5 for entry. Virology 361 (1), 212–228.
Pugach, P., Ray, N., Klasse, P.J., Ketas, T.J., Michael, E., Doms, R.W., Lee, B., Moore, J.P.,
2009. Inefﬁcient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex
at low cell surface CCR5 densities. Virology 387 (2), 296–302.
Rizzuto, C., Sodroski, J., 2000. Fine deﬁnition of a conserved CCR5-binding region on the
human immunodeﬁciency virus type 1 glycoprotein 120. AIDS Res. Hum. Retro-
viruses 16 (8), 741–749.
Rizzuto, C.D., Wyatt, R., Hernandez-Ramos, N., Sun, Y., Kwong, P.D., Hendrickson, W.A.,
Sodroski, J., 1998. A conserved HIV gp120 glycoprotein structure involved in
chemokine receptor binding. Science 280 (5371), 1949–1953.
Schurmann, D., Fatkenheuer, G., Reynes, J., Michelet, C., Rafﬁ, F., van Lier, J., Caceres, M.,
Keung, A., Sansone-Parsons, A., Dunkle, L.M., Hoffmann, C., 2007. Antiviral activity,
pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day
monotherapy in HIV-infected adults. Aids 21 (10), 1293–1299.
Seibert, C., Ying,W., Gavrilov, S., Tsamis, F., Kuhmann, S.E., Palani, A., Tagat, J.R., Clader, J.W.,
McCombie, S.W., Baroudy, B.M., Smith, S.O., Dragic, T., Moore, J.P., Sakmar, T.P., 2006.
Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 349 (1),
41–54.
Tsamis, F., Gavrilov, S., Kajumo, F., Seibert, C., Kuhmann, S., Ketas, T., Trkola, A., Palani, A.,
Clader, J.W., Tagat, J.R., McCombie, S., Baroudy, B., Moore, J.P., Sakmar, T.P., Dragic,
T., 2003. Analysis of the mechanism by which the small-molecule CCR5 antagonists
SCH-351125 and SCH-350581 inhibit human immunodeﬁciency virus type 1 entry.
J. Virol. 77 (9), 5201–5208.
Tsibris, A.M., Sagar, M., Gulick, R.M., Su, Z., Hughes, M., Greaves, W., Subramanian, M.,
Flexner, C., Giguel, F., Leopold, K.E., Coakley, E., Kuritzkes, D.R., 2008. In vivo
emergence of vicriviroc resistance in a human immunodeﬁciency virus type 1
subtype C-infected subject. J. Virol. 82 (16), 8210–8214.
Westby, M., Smith-Burchnell, C., Mori, J., Lewis, M., Mosley, M., Stockdale, M., Dorr, P.,
Ciaramella, G., Perros, M., 2007. Reduced maximal inhibition in phenotypic
susceptibility assays indicates that viral strains resistant to the CCR5 antagonist
maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81 (5), 2359–2371.
Whitcomb, J.M., Huang,W., Fransen, S., Limoli, K., Toma, J., Wrin, T., Chappey, C., Kiss, L.D.,
Paxinos, E.E., Petropoulos, C.J., 2007. Development and characterization of a novel
single-cycle recombinant-virus assay to determine human immunodeﬁciency virus
type 1 coreceptor tropism. Antimicrob. Agents Chemother. 51 (2), 566–575.
Wu, L., Gerard, N.P., Wyatt, R., Choe, H., Parolin, C., Rufﬁng, N., Borsetti, A., Cardoso, A.A.,
Desjardin, E., Newman,W., Gerard, C., Sodroski, J., 1996. CD4-induced interaction of
primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature
384 (6605), 179–183.
Wu, L., LaRosa, G., Kassam, N., Gordon, C.J., Heath, H., Rufﬁng, N., Chen, H., Humblias,
J., Samson, M., Parmentier, M., Moore, J.P., Mackay, C.R., 1997. Interaction of
chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120
binding and a single domain for chemokine binding. J. Exp. Med. 186 (8),
1373–1381.
Wyatt, R., Kwong, P.D., Desjardins, E., Sweet, R.W., Robinson, J., Hendrickson, W.A.,
Sodroski, J.G., 1998. The antigenic structure of the HIV gp120 envelope
glycoprotein. Nature 393 (6686), 705–711.
Wyatt, R., Sodroski, J., 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and
immunogens. Science 280 (5371), 1884–1888.
